Nasopharyngeal Diseases  >>  cisplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
NCT00565448 / 2007-001211-33: Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

Completed
2
75
Europe, RoW
docetaxel, Taxotere®, XRP6976, cisplatin, 5-fluorouracil, 5-FU
Sanofi
Nasopharyngeal Neoplasms, Carcinoma
03/09
01/12
NCT00439426: A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.

Completed
2
25
RoW
Oxaliplatin, capecitabine [Xeloda]
Hoffmann-La Roche
Nasopharyngeal Cancer
09/09
09/09
NCT00436293: Taxotere + Cisplatin in Nasopharyngeal Carcinoma

Completed
2
61
RoW
Docetaxel, Cisplatin
Sanofi
Nasopharyngeal Neoplasms
03/10
03/10
NCT00603915: A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer

Completed
2
20
Canada
Gemcitabine, Carboplatin/Cisplatin, erlotinib
University Health Network, Toronto, Hoffmann-La Roche
Nasopharyngeal Cancer
12/10
04/11
NCT01326559: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

Completed
2
33
RoW
Docetaxel, Cisplatin, 5-FU and Cetuximab
Hong Kong Nasopharyngeal Cancer Study Group Limited, The University of Hong Kong, Sanofi, Merck Sharp & Dohme LLC, Roche Pharma AG
Nasopharyngeal Carcinoma
12/16
03/17

Download Options